
    
      Eurobact II is a multinational multicentre cohort study that will include patients with
      hospital-acquired blood stream infections (HA-BSI) treated in ICUs around the globe. It will
      provide with an update of the epidemiology of HA-BSI since the Eurobact I study. It is
      designed to investigate the effects of HA-BSI on mortality at day 28. To describe the
      determinants of outcomes of HA-BSI, specifically the effects of the source of infection, the
      microorganism, the characteristics of antimicrobial therapy and of source control. It will
      investigate patient specific and organizational factors and will describe the determinants of
      management of HA-BSI in ICUs.
    
  